Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

43.54
-0.4600-1.05%
Post-market: 43.610.0700+0.16%19:56 EDT
Volume:2.31M
Turnover:100.67M
Market Cap:7.24B
PE:-12.51
High:44.17
Open:44.17
Low:43.24
Close:44.00
52wk High:86.74
52wk Low:43.01
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.63
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:16.45
PE(LYR):-18.28

Loading ...

Ionis Pharmaceuticals price target lowered to $104 from $110 at Morgan Stanley

TIPRANKS
·
Sep 08

Ionis Pharmaceuticals, Inc. : TD Cowen Cuts Target Price to $84 from $94

THOMSON REUTERS
·
Sep 08

Canaccord Genuity Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 08

Ionis Pharmaceuticals Price Target Cut to $100.00/Share from $115.00 by HC Wainwright & Co.

Dow Jones
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 08

Movement Alert|Ionis Pharmaceuticals Falls 12.19% in Pre-Market Trading, Partner Novartis Lp(a) Drug Pelacarsen Fails Phase 3 Cardiovascular Outcomes Trial

Market Focus
·
Sep 08

Ionis Pharmaceuticals price target lowered to $56 from $69 at Goldman Sachs

TIPRANKS
·
Sep 08

Ionis Pharma Shares Down 13.1% Premarket After Co's Heart Drug Fails Late-Stage Trial

THOMSON REUTERS
·
Sep 08

Ionis Pharma Tumbles After Heart Drug Fails Late-Stage Trial

Reuters
·
Sep 08

Movement Alert|Ionis Pharmaceuticals Falls 9.78% Overnight, Partner Novartis Pelacarsen Phase 3 Cardiovascular Outcomes Trial Fails to Meet Primary Endpoint

Market Focus
·
Sep 08

Citi sees limited immediate downside for Ionis after pelacarsen failure

TIPRANKS
·
Sep 07

Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex

Dow Jones
·
Sep 05

Ionis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome

TIPRANKS
·
Sep 05

Novartis announces Phase 3 pelacarsen study did not meet primary endpoint

TIPRANKS
·
Sep 05

Ionis-Novartis Heart Drug Misses Main Goal of Late-Stage Trial

Reuters
·
Sep 05

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

Dow Jones
·
Sep 05

Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside

TIPRANKS
·
Sep 05

Movement Alert|Ionis Pharmaceuticals Falls 9.43% in After-Hours Trading, FDA Approval of Alexander Disease Drug Triggers Sell-the-News Reaction

Market Focus
·
Sep 05

Ionis Pharmaceuticals (IONS) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 05

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Dow Jones
·
Sep 05